Meet the Cheapest Stock in the "Magnificent Seven" Right Now. Is it a Buy?
Let's meet the cheapest stock in the Magnificent Seven right now -- and consider whether it's a buy. Some of these players ...
Solid Biosciences Stock Surges On Upbeat Duchenne Muscular Dystrophy Gene Therapy Data
Solid Biosciences' SGT-003 gene therapy showed strong dystrophin expression, muscle health improvements, and no serious safety concerns in early trial data.
Growth stocks are still doing quite well in 2025, without any help from the 'Magnificent Seven'
Members of the "Magnificent Seven" have struggled in 2025. But growth stocks, a broader group of companies with similar ...
Solid Biosciences Shares Rise After Positive Trial Data for SGT-003 in Duchenne MD
Solid Biosciences shares were up 50% to $6.06 after the company said it saw positive initial data from a Phase 1/2 trial evaluating SGT-003, a gene therapy product candidate intended for the treatment ...
Old Economy vs. New Economy Stocks: What's the Difference?
Learn the differences between old economy stocks that represent large, established companies and new economy stocks such as tech companies.